Screener
Arcutis Biotherapeutics, Inc. ARQT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of long-term debt, net | 6,950 | 1,000 |
| Accrued and other current liabilities | 146,786 | 116,310 |
| Total current liabilities | 160,340 | 129,838 |
| Operating lease liability, long-term | 5,237 | 5,266 |
| Long-term debt, net | 101,950 | 107,959 |
| Other long-term liabilities | 431 | 431 |
| Total liabilities | 267,958 | 243,494 |
| Commitments and contingencies (Note 7) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported operating lease liabilities of $5.24M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s operating lease liabilities increased by 147.7% year-over-year, from $2.11M to $5.24M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s operating lease liabilities has grown at a 1.2% compound annual growth rate (CAGR), from $4.96M to $5.27M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Arcutis Biotherapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude